Last reviewed · How we verify
NCT03452202
Using tDCS in Speech-based Stroke Rehabilitation
NA trial testing Soterix 1x1 line tDCS low-intensity stimulator in Apraxia of Speech in 24 participants. Currently enrolling.
30 October 2026
Quick facts
| Lead sponsor | NYU Langone Health |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 11 January 2019 |
| Primary completion | 30 October 2026 |
| Estimated completion | 30 October 2026 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Soterix 1x1 line tDCS low-intensity stimulator
- Sham
Conditions studied
- Apraxia of Speech — all drugs for Apraxia of Speech →
Sponsor
NYU Langone Health — full company profile →
Who can join
Adults 18 to 99, any sex, with Apraxia of Speech. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine whether the effect of treatment for acquired speech impairment can be enhanced by combining effective behavioral treatment with non-invasive brain stimulation. Transcranial direct current stimulation (tDCS), which delivers low-intensity current to the scalp, and is a safe and well-tolerated approach that poses a non-significant risk to participants. tDCS provides low intensity neural stimulation which has been shown to facilitate motor learning in other domains of stroke rehabilitation such as arm motor learning but the potential to enhance speech motor learning has not been explored. This will be examined with a series of single-case experimental designs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03452202
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Apraxia of Speech
Currently open trials in the same condition.
- NCT06512168 — Measuring Aided Language Development · NA · recruiting
- NCT06467136 — Motor Imagery for Treatment Enhancement and Efficacy in Persons With Apraxia of Speech · NA · recruiting
- NCT05368350 — Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation · NA · active not recruiting
- NCT04604444 — Changes in Neuroplasticity Following Intensive Rehabilitation of Aphasia and/or Apraxia of Speech · NA · recruiting
Other NYU Langone Health trials
Trials by the same sponsor.
- NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
- NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
- NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
- NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
- NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03452202 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
- Last refreshed: 29 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03452202.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing